In an attempt to diversify its portfolio, Biogen has agreed to pay Roche’s Genentech US$30 M to participate in the development and commercialisation of the latter’s late-stage CD20xCD3 bispecific antibody, mosunetuzumab. The drug is currently in development for the treatment of patients with B-cell non-Hodgkin’s lymphoma, including follicular lymphoma and diffuse B-cell lymphoma. This deal builds upon the companies’ multidecade partnering history which has led to the approval of cancer drugs, Gazyva and bestseller Rituxan.